AML


Associated tags: Acute myeloid leukemia, Bone marrow, AML, Acute leukemia, Blood, Pharmaceutical industry, Patient, Gene expression, MDS, Safety, Cancer, Therapy, Foghorn, Chromatin, BRM

Locations: UNITED STATES, TEXAS

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, March 26, 2024
BRM, CBP, Foghorn, Webcast, SMARCA2, EP300, AACR, Conference, Conference call, Acute leukemia, Gene expression, AML, Pharmaceutical industry

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.

Key Points: 
  • Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs
    Conference call and webcast on April 9th at 5 p.m.
  • ET / 2 p.m. PT
    CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m.
  • ET / 2 p.m. PT.
  • Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Retrieved on: 
Thursday, April 4, 2024
Platelet transfusion, CRi, CRC, Patient, Rigel, SAN, CRH, AML, Pharmaceutical industry

"Venetoclax in combination with a hypomethylating agent is currently standard treatment for patients with newly diagnosed AML who are unfit for intensive chemotherapy, including those with mIDH1.

Key Points: 
  • "Venetoclax in combination with a hypomethylating agent is currently standard treatment for patients with newly diagnosed AML who are unfit for intensive chemotherapy, including those with mIDH1.
  • "The findings from these analyses suggest that REZLIDHIA may provide an effective treatment for patients with AML following failure of venetoclax combination therapy.
  • "These data support REZLIDHIA's efficacy and well-characterized safety profile in patients with mIDH1 R/R AML who had previously been treated with venetoclax combination regimens," said Raul Rodriguez, Rigel's president and CEO.
  • Both patients with CRi at study entry achieved CR
    Median time to CRc was 1.9 months (range 1-2.8).

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Retrieved on: 
Thursday, March 7, 2024
EP300, NSCLC, Merck, Research, AML, Neoplasm, ARID1B, Investment, CBP, Cancer, Prostate, AACR, Factorization of polynomials, Lung cancer, Safety, MDS, Collaboration, Gene expression, Thrombocytopenia, Lilly, Medicine, Patient, Survival, IND, LDAC, Development, Colorectal cancer, BRM, Chromatin, Prostate cancer, Pharmaceutical industry

“In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.

Key Points: 
  • “In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.
  • The IND is planned for the second quarter of 2024, with an initial focus in non-small cell lung cancer.
  • The Company is conducting preclinical work to further explore the opportunity and expects data in the second quarter of 2024.
  • Foghorn is presenting new preclinical data for its CBP and EP300 selective degrader programs at the 2024 AACR Annual Meeting, April 5-10, 2024.

AML Will Launch Dragonfly Wearable Computer at MODEX 2024

Retrieved on: 
Monday, February 26, 2024
Android 13, Qualcomm, Dragonfly, Warehouse

RICHLAND HILLS, Texas, Feb. 26, 2024 /PRNewswire-PRWeb/ -- AML, a U.S.-based manufacturer of barcode data collection products, will launch its Dragonfly Wearable Computer at the upcoming MODEX Supply Chain Expo, (Booth # C7288), being held in Atlanta March 11-14, 2024.

Key Points: 
  • AML (Booth C7288) will be introducing Dragonfly, our first wearable computing solution designed for hands-free applications.
  • RICHLAND HILLS, Texas, Feb. 26, 2024 /PRNewswire-PRWeb/ -- AML, a U.S.-based manufacturer of barcode data collection products, will launch its Dragonfly Wearable Computer at the upcoming MODEX Supply Chain Expo , (Booth # C7288), being held in Atlanta March 11-14, 2024.
  • The Dragonfly Wearable Computer is equipped with the most powerful processing architecture available for devices in its class, featuring the Qualcomm 6490 processor running Android 13 at 2.7 GHz.
  • The wearable computer is backed by an array of software utilities for rapid deployment, remote device management, and secure web browsing.

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Retrieved on: 
Wednesday, January 17, 2024
Risk, Phenotype, Lymphocyte, AML, Patient, Pharmaceutical industry

CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2, multicenter, open-label, first-in-human study of VCAR33ALLO.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2, multicenter, open-label, first-in-human study of VCAR33ALLO.
  • The Company has extended its cash runway into the second half of 2025.
  • “We are pleased to start 2024 with strong execution and we look forward to sharing initial clinical data from the VBP301 trial later this year,” said Dr. Eyal Attar, Vor Bio’s Chief Medical Officer.
  • While this first patient had relapsed after a standard-of-care transplant, patients who have relapsed after a trem-cel transplant are also eligible to enroll in the VBP301 protocol and to receive VCAR33ALLO.

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

Retrieved on: 
Monday, January 8, 2024
LDAC, Medicine, IND, Colorectal cancer, EGFR, BRG1, Prostate cancer, Factorization of polynomials, MDS, Thrombocytopenia, Gene expression, Chromatin, Neoplasm, Prostate, CBP, Cancer, Patient, Safety, ARID1B, AML, NSCLC, BRM, EP300, Pharmaceutical industry

This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.

Key Points: 
  • This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.
  • Over the next four years, we anticipate the filing of at least six new INDs, reflecting the productivity of our precision medicine platform.
  • This is all supported by our cash and equivalents position of approximately $259.9 million as of September 30, 2023.”
    FHD-286.
  • Foghorn is engaged in a strategic collaboration with Loxo@Lilly and continues to advance the BRM selective inhibitor and degrader programs along with other undisclosed programs.

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Retrieved on: 
Thursday, November 9, 2023
Aplastic anemia, Webcast, Baptist Health South Florida, Transplant, Toxicity, ASH, Acute myeloid leukemia, Leukemia, Patient, Conference, CD33, Pediatric Transplantation, AML, Doctor of Philosophy, Cytokine release syndrome, Pharmaceutical industry, Gemtuzumab ozogamicin, MD

Additionally, platelet recovery occurred at a median of 15.5 days, excluding one patient with previously documented anti-platelet antibodies (immune thrombocytopenia).

Key Points: 
  • Additionally, platelet recovery occurred at a median of 15.5 days, excluding one patient with previously documented anti-platelet antibodies (immune thrombocytopenia).
  • This data further validates Vor Bio’s approach of using transplant donor cells as CAR-T starting material that are healthy, stem-like, and exactly matched to the patient’s immune system.
  • Vor Bio management will host a live webcast today at 4:30 PM ET.
  • A replay of the webcast will be available via the investor section of the Company’s website at www.vorbio.com approximately two hours after the call’s conclusion.

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers

Retrieved on: 
Friday, December 8, 2023
Rigel, SAN, Food, Acute myeloid leukemia, Patient, Myelocyte, FDA, MPN, Monroe Dunaway Anderson, MDS, IDH1, Pancreatic serous cystadenoma, University, AML, MD Anderson Cancer Center, Cancer, Mutation, Pharmaceutical industry, Leukemia

Under the strategic collaboration, Rigel and MD Anderson will evaluate the potential of olutasidenib to treat newly diagnosed and relapsed or refractory (R/R) patients with AML, higher-risk myelodysplastic syndromes (MDS), and advanced myeloproliferative neoplasms (MPN), in combination with other agents.

Key Points: 
  • Under the strategic collaboration, Rigel and MD Anderson will evaluate the potential of olutasidenib to treat newly diagnosed and relapsed or refractory (R/R) patients with AML, higher-risk myelodysplastic syndromes (MDS), and advanced myeloproliferative neoplasms (MPN), in combination with other agents.
  • "We are excited to enter into this strategic alliance with the exceptional team at MD Anderson to evaluate REZLIDHIA as a potential therapy for a broad range of IDH1-mutant cancers," said Raul Rodriguez, Rigel's president and CEO.
  • We look forward to a close collaboration with MD Anderson to advance this as a new therapeutic option for more patients."
  • Rigel and MD Anderson will jointly lead all clinical development efforts, which will be overseen by a joint steering committee.

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Retrieved on: 
Thursday, November 2, 2023
Research, NSCLC, EP300, IND, Thrombocytopenia, MDS, Preclinical development, Colorectal cancer, Merck, Chromatin, Factorization of polynomials, Prostate cancer, Hanson, LDAC, ARID1B, Clinical trial, CBP, BRG1, BRM, Safety, Investment, AR, Patient, Gene expression, BAF, Prostate, Mutation, State Administrative Expenses, Cancer, Pharmaceutical industry, Vaccine, Decitabine, Foghorn, AML

“During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.

Key Points: 
  • “During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.
  • Foghorn commenced a Phase 1 study of FHD-286 in combination with decitabine or low-dose cytarabine (LDAC) in relapsed and/or refractory AML patients, with the first patient dosed during the third quarter of 2023.
  • As of September 30, 2023, the Company had $259.9 million in cash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026.
  • Net loss was $14.3 million for the three months ended September 30, 2023, compared to a net loss of $25.8 million for the three months ended September 30, 2022.

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023
CR, IVO, VEN, Haematopoiesis, Constipation, Platelet, Acute myeloid leukemia, CRC, Prior, Thrombocytopenia, Vomiting, MDS, Diarrhea, Treatment, Rigel, Fostamatinib, Bone marrow, Hematopoietic stem cell transplantation, CRH, CRi, Inflammation, Azacitidine, Nausea, Society, Progress, ASH, Poster, Myelodysplastic syndrome, Cell death, Relapse, ITP, SAN, ORR, University, Safety, Venetoclax, IRAK, Cellular, MD Anderson Cancer Center, Cytopenia, Transplant, Neutropenia, AML, HSCT, Fatigue, Pharmaceutical industry, Dentistry, Dietary supplement, Bookkeeping, Vaccine, Patient, Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually.

Key Points: 
  • "We are also excited by the compelling data in patients with mIDH1 MDS and look forward to evaluating this potential opportunity further.
  • On top of the olutasidenib data, we are delighted to share other updates and data across our development portfolio, demonstrating our presence in the hematology-oncology space."
  • These results support the use of fostamatinib as a second-line treatment in patients with primary ITP.
  • To learn more about Rigel Pharmaceuticals and their clinical and commercial hematology/oncology portfolio visit Booth #2805 during ASH 2023.